Evotec SE (EVO) stock
Close on Nov 11, 2026Market cap $600.89MP/E –Yield –
Evotec SE saw revenue fall 1.1% to €788.37M over fiscal 2025. Free cash flow was -€81.72M. At the latest close the market valued the company at €538.72M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- €538.72M
- P/E ratio
- –
- Price to sales
- 0.68
- Price to book
- 0.66
- Dividend yield
- –
- Free cash flow yield
- -15.17%
Fundamentals
- Revenue
- €788.37M
- EPS, diluted
- -0.58 EUR
- Free cash flow
- -€81.72M
Trading
- Previous close
- $1.69
- Open
- $1.66
- Day's range
- $1.65 – $1.72
- Volume
- 61,660
- Average volume (20 days)
- 81,796
- Beta (5 years)
- 1.25
- RSI (14 days)
- 56.5
- Volatility (1 year)
- 56.5%
- Relative volume
- 0.63×
- WACC
- 10.4%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | EVO | S&P 500 | Difference | EVO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +10.5% | -2.4% | +12.9 pts | ||
| 3 months | -19.5% | -1.2% | −18.4 pts | ||
| Year to date | -45.1% | +12.3% | −57.4 pts | ||
| 1 year | -43.1% | +12.4% | −55.5 pts | ||
| 3 years | -81.9% | +78.8% | −160.7 pts | -43.4% | +21.4% |
| 5 years | -92.8% | +75.2% | −168.0 pts | -40.9% | +11.9% |
| 10 years | -38.9% | +311.1% | −350.0 pts | -4.8% | +15.2% |
Eight years at a glance
Fiscal years 2018 to 2025, EUR
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Evotec filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Evotec
Pharmaceutical Preparations
Evotec operates as a drug discovery and development partner providing research services and solutions to the pharmaceutical and biotechnology industries. The company conducts collaborative research and development across two principal operating segments: Shared R&D and Just - Evotec Biologics. Its offerings include fee-based research, full-time equivalent research payments, integrated data analytics platforms such as PanHunter and molecular patient databases, and technology licensing. Evotec primarily serves commercial biopharmaceutical organizations and healthcare partners.
Company profile, executives and historyEvotec stock: common questions
What is Evotec's stock price?
EVO closed at $1.69 on Nov 11, 2026, up 0.00% on the day.
What is Evotec's market cap?
Evotec was worth $600.89M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is EVO's P/E ratio?
Evotec lost money over fiscal 2025 (diluted EPS -0.58 EUR), so it has no meaningful P/E ratio.
How much revenue does Evotec make?
Evotec reported revenue of €788.37M for fiscal 2025, down 1.1% from a year earlier.
Does Evotec pay a dividend?
No. Evotec has not paid a cash dividend over the last twelve months.
How has EVO stock performed over the past year?
Including dividends, EVO returned -43.1% over the past year, against +12.4% for the S&P 500.
Who are Evotec's competitors?
Companies most similar to Evotec by business, industry and size include PTGX, HCM, RARE, AAPG, TLX.
See a number that looks wrong?